Skip to content
value.today

scPharmaceuticals Inc.

SCPHUnlisted company
$228 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
Dec-2020 ending year
value.today research
Net income
$-32 M
value.today research
Employees
—

scPharmaceuticals Inc. in brief

scPharmaceuticals Inc. is an unlisted company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2013. In the year to Dec 2020 it had sales of $0 M and a net loss of $32 M.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

scPharmaceuticals Inc. timeline

2 events, 2013–2017
  1. 2013
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of scPharmaceuticals Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about scPharmaceuticals Inc.

Acquisitions and changes
No longer listed: ticker SCPH is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$81 M$162 M$243 M$324 M20202021202220232024

World rank over time

▲ up 1,126 places since 2020
2020-01-01: #18339#18,33920202021-01-01: #16692#16,69220212022-01-07: #21276#21,27620222022-12-25: #17732#17,73220222023-07-30: #15838#15,83820232024-01-05: #17213#17,2132024

Rank in USA: #3,637 (Jan 2020) · #3,451 (Jan 2021) · #4,192 (Jan 2022) · #3,623 (Dec 2022) · #3,215 (Jul 2023) · #3,147 (Jan 2024)

Annual results

Revenue
$0 M
Operating income
—
Net income
$-32 M

Dec-2020 ending year

Mutual funds holding scPharmaceuticals Inc.#

1 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
Mutual funds holding scPharmaceuticals Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 The Gabelli ABC FundGabelli Funds, LLC22,000$0 M—<0.01%no changeJun 30, 2026

As of Jun 30, 2026

Markets and events: scPharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-09-30
1.1 M
1 days to cover
Shares sold short, last 22 reportsAll stocks →

Trading halts

  • 2025-10-06 23:50 UTC, code D, resumed 04:00 UTC
  • 2025-08-25 11:25 UTC, code T3, resumed 12:00 UTC

Fails to deliver

  • : 2 shares at $5.67
  • : 22 shares at $5.63
  • : 400 shares at $5.63
  • : 2 shares at $5.62
  • : 310 shares at $5.61

Lobbying by scPharmaceuticals Inc.#

$50 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid and health issues.

Lobbying, 2025
$50 K
#1,361 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$13 K
  • Medicare/Medicaid4 reports
  • Health Issues4 reports

Lobbying firms hired in 2025

JEFFREY J. KIMBELL AND ASSOCIATES $50 K

scPharmaceuticals Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$13 K—1
2025$50 K—4
2024$50 K—4
2023$13 K—1

H-1B hiring at scPharmaceuticals Inc.#

2 labor condition applications certified in fiscal 2024 for 2 positions, at a median wage of $124 K a year.

Certified, FY2024
2
#1,598 among companies on value.today
Worker positions
2
Median wage offered
$124 K
a year, full-time
Applications filed
2
scPharmaceuticals Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Manager, Medical Affairs & PharmacovigilanceCompliance Managers1$126 K
Regulatory Affairs ManagerRegulatory Affairs Managers1$121 K

Where: Burlington, MA 2

scPharmaceuticals Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202422$124 K2
FY202122$87 K2

How scPharmaceuticals Inc. compares in Biotechnology

  • Revenue$0 M · higher than 0% of 647

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
scPharmaceuticals Inc.🇺🇸$228 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Annual results:
Dec-2020 ending year
Balance sheet:
Dec-2020 ending year
Profile updated:
Nov 14, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at scPharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show scPharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about scPharmaceuticals Inc.? Suggest a correction